Allstocks.com's Bulletin Board Post New Topic  Post A Reply
my profile login | register | search | faq | forum home

  next oldest topic   next newest topic
» Allstocks.com's Bulletin Board » .11 and Up! » ***PKTX..We Have PR News..!!

 - UBBFriend: Email this page to someone!    
Author Topic: ***PKTX..We Have PR News..!!
jackbequick
Member


Rate Member
Icon 14 posted      Profile for jackbequick     Send New Private Message       Edit/Delete Post   Reply With Quote 
***PKTX..We Have PR News.. :+O
ProtoKinetix AAGP® Molecule Moving Forward in Key Healthcare Studies Targeting Important Health Care SolutionsPress Release | 09/04/2018

ProtoKinetix, Incorporated (www.protokinetix.com) (the "Company" or "ProtoKinetix") (OTCQB:PKTX)

...President and Chief Executive Officer Clarence Smith is pleased at the progress of the health care applications projects the Company has underway. According to Mr. Smith “To that end, ProtoKinetix is continuing to collaborate with some of the most prestigious research institutions.

..The Company is focusing on research efforts in areas where our AAGP® molecule can significantly impact the success of healthcare outcomes.”
***I invite you to click on the links below for more detailed information.

***The company plans to introduce video content to its website that will allow for more detailed updates.

Current projects underway include the following:

1. Solutions for Diabetes
Diabetes study currently in a Phase 1 human trial.
Clinicaltrials.gov - Islet Transplantation Using PKX-001.

2. Solutions for blindness from age related macular degeneration
Retinal Cell Replacement study has started Phase 3.
https://www.protokinetix.com/news/2018/august10/

3. Immunology Studies

a) Cord Blood Stem Cell Storage and Recovery.
b) Cord Blood Stem Cell Transplantation and Engraftment.
c) Monoclonal Antibodies, ‘study completed’.

https://www.protokinetix.com/news/2018/january10/

4. Solutions Enabling Healthy Survival of Strokes and Heart Attacks
AAGP® Projects for Cardiac/Heart Research includes:

a) Suppression of doxorubicin toxicity
b) Glucolipotoxity protection
c) Endoplasmic reticulum stress mediation
d) Ischemic damage repair
e) Whole heart ex-vivo preservation

Research being conducted under proprietary MTA agreements include:

5. Solutions enabling increased healthy numbers of life saving stem cells
Material Transfer Agreement ‘A’ includes studies for:
https://www.protokinetix.com/news/2018/june13/

a) Cryopreservation of primary mammalian tissue cells
b) Enhancing the viability of primary mammalian cells
c) Cell lines under stressed culture conditions

6. Material Transfer Agreement ‘B’ includes studies for:
https://www.protokinetix.com/news/2017/june5/

a) Immune Cell Cryopreservation recovery, ‘study completed’

In Our Current Pipeline:

Two studies with an undetermined start dates are Kidney Ischemia and Liver Perfusion.
The company is actively negotiating material transfer agreements with other companies for collaborative research studies.
CEO Clarence Smith notes that the company has adequate cash on hand for project continuation and company operations for the near term.

IP: Logged | Report this post to a Moderator
   

Quick Reply
Message:

HTML is enabled.
UBB Code™ is enabled.

Instant Graemlins
   


Post New Topic  Post A Reply Close Topic   Feature Topic   Move Topic   Delete Topic next oldest topic   next newest topic
 - Printer-friendly view of this topic
Hop To:


Contact Us | Allstocks.com Message Board Home

© 1997 - 2021 Allstocks.com. All rights reserved.

Powered by Infopop Corporation
UBB.classic™ 6.7.2

Share